

Technological University Dublin ARROW@TU Dublin

Articles

2022-01-17

Ultrasound 96 Probe Device Protocol for cancer cell treatment

Aisling Field

Technological University Dublin

Brijesh K. Tiwari Teagasc Ashtown Food Research Centre

James F. Curtin

Technological University Dublin, james.curtin@tudublin.ie

See next page for additional authors

Follow this and additional works at: https://arrow.tudublin.ie/creaart

Part of the Biochemistry Commons, Cancer Biology Commons, Cell Biology Commons, Medical Biochemistry Commons, and the Medical Biophysics Commons

Recommended Citation

Aisling Field, Brijesh Tiwari, James F Curtin, Julie Rose Mae Mondala, Janith Wanigasekara 2022. Ultrasound 96 Probe Device Protocol for cancer cell treatment. protocols.io. DOI: 10.17504/protocols.io.b3udqns6

This Article is brought to you for free and open access by ARROW@TU Dublin. It has been accepted for inclusion in Articles by an authorized administrator of ARROW@TU Dublin. For more information, please contact arrow.admin@tudublin.ie, aisling.coyne@tudublin.ie, gerard.connolly@tudublin.ie.



This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License

Funder: Science Foundation Ireland (SFI)



| Authors Aisling Field, Brijesh K. Tiwari, James F. Curtin, Julie R M Mondala, and Janith Wanigasekara |
|---|
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |



JAN 17, 2022

OPEN ACCESS

DOI:

dx.doi.org/10.17504/protocol s.io.b3udqns6

Protocol Citation: Aisling
Field, Brijesh Tiwari, James F
Curtin, Julie Rose Mae
Mondala, Janith Wanigasekara
2022. Ultrasound 96 Probe
Device Protocol for cancer cell
treatment. protocols.io
https://dx.doi.org/10.17504/p
rotocols.io.b3udqns6

MANUSCRIPT CITATION:

Deprez, J., Lajoinie, G., Engelen, Y., De Smedt, S., & Lentacker, I. (2021). Opening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery. Advanced Drug Delivery Reviews, 172, 9-36. doi:

10.1016/j.addr.2021.02.015. Pitt, W., Husseini, G., & Staples, B. (2004). Ultrasonic drug delivery – a general review. Expert Opinion On Drug Delivery, 1(1), 37-56. doi:

10.1517/17425247.1.1.37 Wanigasekara, J., de Carvalho, A., Cullen, P., Tiwari, B., & Curtin, J. (2021). Converging technologies: targeting the hallmarks of cancer using ultrasound and microbubbles. Trends In Cancer, 7(10), 886-890. doi:

10.1016/j.trecan.2021.07.00

Ultrasound 96 Probe Device Protocol for cancer cell treatment

Forked from a private protocol

Aisling Field¹, Brijesh Tiwari², <u>James F Curtin</u>¹, <u>Julie Rose Mae Mondala</u>¹, <u>Janith Wanigasekara</u>¹

¹Technological University Dublin; ²Teagasc Food Research Centre Dublin

Technological University Dublin



James F Curtin
<u>Technological University Dublin</u>

DISCLAIMER

DISCLAIMER - FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

License: This is an open access protocol distributed under the terms of the <u>Creative Commons</u>
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working We use this protocol and it's working

Created: Jan 13, 2022

Last Modified: Jan 17, 2022

PROTOCOL integer ID: 56933

Keywords: Ultrasound, Cancer treatment

ABSTRACT

Ultrasound is a sound wave with frequencies ranging between 20 kHz and 20 MHz. Ultrasound is able to temporarily and repeatedly open the BBB safely and enhance chemotherapeutic delivery without adverse effects. (Deprez et al., 2021). This novel technique in drug delivery benefits from the powerful ability of ultrasound to produce cavitation activity. Cavitation is the generation and activity of gas-filled bubbles in a medium exposed to ultrasound. As the pressure wave passes through the media, gas bubbles expand at low pressure and contract at high pressure. This leads to oscillation which produces a circulating fluid flow known as microstreaming around the bubble with velocities and shear rates proportional to the amplitude of the oscillation. At high amplitudes the associated shear forces can cut open liposomes (Wanigasekara et al., 2021; Deprez et al., 2021).

Vesicles denser than the surrounding liquid are drawn into the shear field surrounding an oscillating bubble. If the shear stress is greater than the strength of the vesicle, it will burst and spill its contents. In a liposome, the vesicle will reform, often at a smaller size than before meeting the shear field. Hence, some interior liquid must be released during the break down. (Pitt et al., 2004)

This protocol describes the use of an ultrasound probe to trigger the release of liposomes in glioblastoma cells. This method uses an ultrasound device which is set to the following parameters: Time = 3 min, Pulse = 59 /01, Amplitude = 20%. The ultrasound technique is an easy and reliable technique making it useful in the study of a variety of areas such as oncology. When applied to an ultrasonic transducer, the Pulser part of the instrument generates short, large amplitude electric pulses of controlled energy, which are transformed into short ultrasonic pulses.

The VCX 750 is the ultrasonic liquid processor used for this experiment. It is powerful

The VCX 750 is the ultrasonic liquid processor used for this experiment. It is powerful and versatile and can process a wide range of sample types and volumes for many different applications.

MATERIALS TEXT

- VCX 750 ultrasonic liquid processor
- 96 probe system
- 96 well plate
- retort stand
- laboratory Jack
- Sonics Vibra cell power unit
- 96-well seed plate
- Nunclon™ Sphera™ 96-Well plate
- Incubator
- Fresh media
- Dimethyl sulfoxide (DMSO) (20%)

SAFETY WARNINGS

- •
- Laboratory coat and gloves must be worn at all times.
- Ear protection must be worn at all times due to the highfrequency sound level of the VCX 750 ultrasonic liquid processor.
- A safe distance must be kept between the operator and the VCX 750 ultrasonic liquid processor while in operation.
- Ensure there is signage advising others that an ultrasound device is in operation.
- 1 Before starting the ultrasound probe system, ensure that all parts of the system/device are free from mechanical damage and that the probe is connected tightly.



Image of the VCX 750 ultrasonic liquid processor

The 96-probe system is designed to fit perfectly into the 96 well plate, which can be used to grow and treat cancer cells. The retort stand is used to hold the Ultrasound 96 probe unit vertically. A laboratory Jack is used to hold the cancer cells grown in the 96 well plate and to move it towards the 96 probes.


A Sonics - Vibra cell power unit is needed to fix into ultrasound 96 probe. Using the power unit, the ultrasound treatment time (0 to 99 min), temperature, pulser, and amplitude can be controlled. Experiments found that the best parameters to use are 20% amplitude, Pulses of 59 seconds on and 1 second off with different time ranges (1, 3, 5, 10, and 20 min).



Data processor unit showing the experiment parameters

- For 2D cell culture assays using a 96-well seed plate, seed cells in 100 μl of the appropriate media. For 3D cell culture assays using a Nunclon™ Sphera™ 96-Well plate, seed cells in 200 μl of the appropriate media. Leave 2D cells to adhere overnight at 37 °C in a humidified atmosphere at a density of 2 x 10^3 cells/well or 1 x 10^4 cells/well for 96 hours incubation time post-treatment and 24 hours incubation time post-treatment, respectively. During 3D cells, spheroids will usually form in 3-7 days from the starting date depending on seeding density.
- 5 On the day of ultrasound treatment, remove the culture media from the plates and add 100µl

fresh media into each plate. It is Important that during ultrasound treatment all the 96 probe tips are immersed inside media/ any liquid). There mustn't be any empty wells, hence 100ul of media





Ultrasound probe submerged in sample

should be added into each well.

- Place the sample (plate without lid) in the centre of the laboratory Jack and slowly move into the 96 probe. 2mm distance must be kept from the bottom of the well to the probe tip during the treatment. After setting up the unit, the device is turned on. The samples are treated with the ultrasound using the parameters that were set.
- Following treatment, remove the sample plates from the probe system and carry out post treatment incubation at 37 °C using 5% CO2. Dimethyl sulfoxide (DMSO) (20%) is used as a positive control. Ultrasound treated cells / tumorspheres are then used for further analysis.